Juan M. Cejalvo
Valencia, VC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications
HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.
Journal: ESMO open
Published: April 11, 2026
Breastfeeding shapes a unique tumor-immune landscape in pregnancy-associated breast cancer from GEICAM-EMBARCAM study.
Journal: Breast cancer research : BCR
Published: March 19, 2026
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer.
Journal: Biomaterials research
Published: December 22, 2025
Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.
Journal: ESMO open
Published: November 25, 2025
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.
Journal: Breast cancer research and treatment
Published: November 04, 2025
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 19, 2025
A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer.
Journal: Cancer research communications
Published: July 25, 2025
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.
Journal: ESMO open
Published: June 16, 2025
Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations.
Journal: ESMO open
Published: May 20, 2025
Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer.
Journal: Molecular medicine (Cambridge, Mass.)
Published: January 13, 2025
Last Updated: 09/26/2026